What is the right choice? Is the answer sodium channel blockers?

Area of Science:

• Pediatric Neurology
• Epileptology
• Clinical Pediatrics

Background:

• Self-limited infantile epilepsy (SeLIE) is a common epileptic syndrome in infants.
• Early diagnosis and effective management are crucial for optimal outcomes.
• Understanding SeLIE's characteristics and treatment responses aids clinical decision-making.

Purpose of the Study:

• To evaluate the clinical characteristics and treatment responses in children with SeLIE.
• To enhance awareness regarding early diagnosis and available treatment options for SeLIE.
• To identify effective first-line medications for achieving seizure freedom in SeLIE.

Main Methods:

• Retrospective analysis of clinical and prognostic data from 72 infants and children diagnosed with SeLIE.
• Evaluation of seizure types, age at diagnosis, and neurodevelopmental status.
• Comparison of the efficacy of different anti-seizure medications as first-line treatment.

Main Results:

• The average age at diagnosis was 7.6 months, with seizure onset around 7 months; 54.1% of patients were male.
• Focal elementary motor seizures were most common in patients with normal neurodevelopment (52.7%).
• While levetiracetam was the most common first-line choice, carbamazepine demonstrated the highest seizure-free rate.

Conclusions:

• SeLIE should be considered in afebrile infants with clustered focal seizures, normal neuromotor development, and normal neuroimaging.
• Sodium channel blockers, such as carbamazepine, show high treatment success and are recommended as first-line medications for favorable outcomes in SeLIE.